Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Trends Mol Med. 2014 Jul;20(7):385-93. doi: 10.1016/j.molmed.2014.03.002. Epub 2014 Apr 3.

Extracellular vesicles: emerging targets for cancer therapy.

Author information

  • 1Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QX, UK.
  • 2Department of Neurology, Massachusetts General Hospital and Neuroscience Program, Harvard Medical School, Boston, MA 2129, USA.
  • 3Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QX, UK. Electronic address: matthew.wood@dpag.ox.ac.uk.

Abstract

Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, are released by almost all cell types, including tumour cells. Through transfer of their molecular contents, EVs are capable of altering the function of recipient cells. Increasing evidence suggests a key role for EV mediated intercellular communication in a variety of cellular processes involved in tumour development and progression, including immune suppression, angiogenesis, and metastasis. Aspects of EV biogenesis or function are therefore increasingly being considered as targets for anticancer therapy. Here, we summarise the current knowledge on the contributions of EVs to cancer pathogenesis and discuss novel therapeutic strategies to target EVs to prevent tumour growth and spread.

Copyright © 2014 Elsevier Ltd. All rights reserved.

KEYWORDS:

cancer therapy; exosomes; extracellular vesicles; metastasis; microvesicles; tumour microenvironment

PMID:
24703619
[PubMed - in process]
PMCID:
PMC4082760
[Available on 2015/7/1]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk